Phase I dose escalation trial of intravenous (IV) infusion of CI-1042 (ONYX-015) in patients with refractory cancer

被引：0
|
作者：
Nemunaitis, J
Cunningham, C
Uprichard, M
Kim, D
机构：
[1] US Oncol, Dallas, TX USA
[2] Mary Crowley Med Res Ctr, Dallas, TX USA
[3] Parke Davis, Ann Arbor, MI USA
[4] Imperial Coll Sch Med, London, England
来源：
CANCER GENE THERAPY | 2000年 / 7卷 / 12期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
O27
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] Phase I dose escalation trial of intravenous infusion of ONYX-015 in patients with refractory cancer
    Nemunaitis, J
    Cunningham, C
    Edelman, G
    Berman, B
    Kirn, D
    CANCER GENE THERAPY, 1999, 6 (06) : S16 - S17
  • [2] A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
    J Nemunaitis
    N Senzer
    S Sarmiento
    Y-A Zhang
    R Arzaga
    B Sands
    P Maples
    A W Tong
    Cancer Gene Therapy, 2007, 14 : 885 - 893
  • [3] A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
    Nemunaitis, J.
    Senzer, N.
    Sarmiento, S.
    Zhang, Y-A
    Arzaga, R.
    Sands, B.
    Maples, P.
    Tong, A. W.
    CANCER GENE THERAPY, 2007, 14 (11) : 885 - 893
  • [4] Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer
    Hamid, O
    Varterasian, ML
    Wadler, S
    Hecht, JR
    Benson, A
    Galanis, E
    Uprichard, M
    Omer, C
    Bycott, P
    Hackman, RC
    Shields, AF
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1498 - 1504
  • [5] Phase I/II study of intra-arterial administration of a replication-selective adenovirus CI-1042 (Onyx-015) in patients with metastatic colorectal carcinoma.
    Reid, T
    Galanis, E
    Abbruzzese, J
    Sze, D
    Andrews, J
    Randlev, B
    Romel, L
    Rubin, J
    Kirn, D
    CLINICAL CANCER RESEARCH, 2000, 6 : 4570S - 4570S
  • [6] Pilot trial of intravenous (IV) infusion of a replication selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 in treatment of refractory cancer patients
    Nemunaitis, J
    Cunningham, C
    Tong, A
    Edelman, G
    Paulson, S
    Mitch, D
    Post, L
    Freeman, S
    CANCER GENE THERAPY, 2003, 10 : S13 - S13
  • [7] Phase I Trial of Intravenous Infusion of Onyx 015 and Enbrel in Solid Tumor Patients
    Edelman, Gerald
    Senzer, Neil
    Nemunaitis, Michael
    Cunningham, Casey
    Sovern, Paige
    Tong, Alex
    Nemunaitis, John
    MOLECULAR THERAPY, 2006, 13 : S144 - S144
  • [8] Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    Nemunaitis, J
    Cunningham, C
    Tong, AW
    Post, L
    Netto, G
    Paulson, AS
    Rich, D
    Blackburn, A
    Sands, B
    Gibson, B
    Randlev, B
    Freeman, S
    CANCER GENE THERAPY, 2003, 10 (05) : 341 - 352
  • [9] Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    J Nemunaitis
    C Cunningham
    A W Tong
    L Post
    G Netto
    A S Paulson
    D Rich
    A Blackburn
    B Sands
    B Gibson
    B Randlev
    S Freeman
    Cancer Gene Therapy, 2003, 10 : 341 - 352
  • [10] Phase I/II trial of ONYX-015 in combination with chemotherapy in patients with advanced sarcomas
    Galanis, E
    Okuno, S
    Lewis, B
    Oliveira, A
    Nascimento, A
    Sloan, J
    Edmonson, J
    Randlev, B
    Uprichard, M
    Rubin, J
    GENE THERAPY, 2001, 8 : S8 - S8
12345